FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GlycoNex's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$-59.39 Mil. GlycoNex's Revenue for the
three
months ended in Dec. 2025 was NT$4.41 Mil. Therefore, GlycoNex's FCF Margin % for the quarter that ended in Dec. 2025 was -1,348.22%.
The historical rank and industry rank for GlycoNex's FCF Margin % or its related term are showing as below:
ROCO:4168'
s FCF Margin % Range Over the Past 10 Years
Min: -102593.31 Med: -13989.5 Max: -456.57
Current: -456.57
During the past 13 years, the highest FCF Margin % of GlycoNex was -456.57%. The lowest was -102593.31%. And the median was -13989.50%.
ROCO:4168's FCF Margin % is ranked worse than 70.85% of 957
companies
in the Biotechnology industry
Industry Median: -84.65
vs ROCO:4168: -456.57
GlycoNex FCF Margin % Related Terms
GlycoNex FCF Margin % Historical Data
* Premium members only.
The historical data trend for GlycoNex's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, GlycoNex's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's FCF Margin % distribution charts can be found below:
* The bar in red indicates where GlycoNex's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoNex (ROCO:4168) has a FCF Margin % of -1,348.22% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #678 out of 957 companies in the Biotechnology industry, placing it in the top 70.8%.
Is GlycoNex's FCF Margin % too high?
GlycoNex's current FCF Margin % is -1,348.22%. Based on the distribution chart, GlycoNex ranks #678 out of 957 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #678 out of 957 companies for FCF Margin %. This places GlycoNex in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GlycoNex and its competitors. GlycoNex's current FCF Margin % is -1,348.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.21, compared to a current price of NT$25.60 — trading 65.5% below its estimated fair value. The current FCF Margin % is -1,348.22%. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current FCF Margin % is -1,348.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$25.60 is trading 65.5% below its estimated GF Value™ of NT$74.21.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
FCF Margin %: -1,348.22%
GF Value™: NT$74.21 vs. price of NT$25.60 (65.5% below fair value)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score
Get the complete analysis for ROCO:4168
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
